DEF: Nurix Therapeutics Sets Date for 2025 Annual Stockholders Meeting, Highlights Progress and Future Goals

Nurix Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on May 19, 2025, highlighting the company's advancements in targeted protein degradation medicines and strategic goals for the upcoming year.

Summary

• Nurix Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on May 19, 2025.
• Stockholders of record as of March 21, 2025, are eligible to vote.
• The meeting will cover the election of three Class II directors, ratification of PricewaterhouseCoopers LLP as the independent accounting firm, and an advisory vote on executive compensation.
• In 2024, Nurix achieved an objective response rate (ORR) of 75.5% in r/r CLL patients and 77.8% in WM patients in Phase 1a/1b clinical trials for bexobrutideg.
• Bexobrutideg received Fast Track designation from the FDA for CLL and WM and PRIME designation from the European Medicines Agency for CLL.
• Nurix ended fiscal year 2024 with $609.6 million in cash and investments.
• In 2025, Nurix plans to initiate pivotal trials for bexobrutideg in CLL and continue dose escalation for NX-2127.
• The company earned $27 million in non-dilutive capital from collaborations in fiscal year 2024.
• The Board of Directors determined that the company's performance met most of the 2024 Corporate Goals and achieved key stretch goals, and that the total level of achievement was 115% of target.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with significant clinical and financial achievements, strategic collaborations, and future growth plans. The management expresses confidence in the company's ability to make a profound impact in oncology and beyond.

Positives

• Bexobrutideg shows promise in clinical trials for CLL and WM.
• Regulatory designations (Fast Track, PRIME) provide potential benefits for bexobrutideg development.
• Strong cash position of $609.6 million allows for pipeline advancement.
• Collaborations provide non-dilutive capital ($27 million in fiscal year 2024).
• AI-driven drug discovery platform (DEL-AI) accelerates the identification of novel degrader-based drugs.
• The Board of Directors determined that the company's performance met most of the 2024 Corporate Goals and achieved key stretch goals, and that the total level of achievement was 115% of target.

Risks

• The document contains forward-looking statements that are subject to risks and uncertainties, including the success of drug candidates, clinical trial outcomes, funding availability, and collaboration partner performance.
• The company's actual activities and results could differ materially from those expressed in forward-looking statements due to various risks and uncertainties.

Future Outlook

2025 is expected to be a transformative year with pivotal trials of bexobrutideg planned to support global regulatory approvals for CLL, continued dose escalation of NX-2127, and nomination of a new wholly owned degrader candidate for IND-enabling research.

Management Comments

• Arthur T. Sands, M.D., Ph.D., President and CEO, expressed pleasure in sharing the significant progress Nurix has made in advancing its mission.
• Management believes that hosting a virtual meeting will enable greater stockholder attendance and participation from any location around the world.
• Management is confident in their ability to make a profound impact in oncology and beyond.

Industry Context

The document highlights Nurix's position as a leader in the field of targeted protein degradation, a novel approach in drug design. The company's progress and collaborations with major pharmaceutical companies like Gilead, Sanofi, and Pfizer reflect the growing interest and investment in this area.

Comparison to Industry Standards

• The document mentions that the Compensation Committee uses a peer group of pre-commercial biopharmaceutical/biotechnology companies with market capitalizations between $175 million and $1.5 billion, headcount generally between 75 and 600 employees, and preference given to companies that went public within the last five years and those located in the San Francisco Bay area or in other biotech hubs.
• The peer group includes companies such as Arcus Biosciences, Arvinas, and Kymera Therapeutics.
• The document also mentions that the Compensation Committee supplemented the 2024 peer group market data with data derived from the Radford 2023 Global Life Science Survey for public pre-commercial biopharmaceutical companies.

Management Changes

Stakeholder Impact

• Shareholders: The company aims to translate discoveries into meaningful clinical benefits for patients and long-term value for shareholders.
• Employees: The company is committed to improving diversity and inclusion in the workplace by creating a values-driven culture and investing in employees' career growth through competitive pay and benefits and development and training.
• Patients: The company aims to improve treatment options for patients with cancer and inflammatory diseases.
• Partners: The company aims to advance strategic business and financial partnerships.

Next Steps

• Initiate pivotal trials of bexobrutideg to support global regulatory approvals for patients with CLL.
• Continue dose escalation of NX-2127 to obtain proof-of-concept in aggressive lymphomas.
• Define an optimal dosing strategy for NX-1607 and consider expansion into selected solid tumor indications.
• Nominate a new wholly owned degrader candidate for IND-enabling research this year.
• Progress IRAK4 degrader toward first-in-human studies with Gilead and STAT6 degrader program with Sanofi toward development candidate nomination.

Key Dates

Keywords

Nurix Therapeutics, Annual Meeting, Bexobrutideg, NX-5948, NX-2127, NX-1607, Protein Degradation, Clinical Trials, FDA, PRIME designation, Fast Track designation, Oncology, Hematology, CLL, WM, DEL-AI platform, Cash Position, Executive Compensation, Board of Directors, Corporate Governance